Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Fuchs CS, et al. Among authors: di bartolomeo m. Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1. Lancet Oncol. 2019. PMID: 30718072 Clinical Trial.
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Di Bartolomeo M, Buzzoni R, Mariani L, Ferrario E, Katia D, Gevorgyan A, Zilembo N, Bordonaro R, Bochicchio AM, Massidda B, Ardizzoia A, Marini G, Aitini E, Schieppati G, Comella G, Pinotti G, Palazzo S, Cicero G, Bajetta E; Italian Trial in Medical Oncology (ITMO) Group; Villa E, Fagnani D, Reguzzoni G, Agostana B, Oliani C, Kildani B, Duro M, Botta M, Mozzana R, Mantovani G. Di Bartolomeo M, et al. Oncology. 2006;71(5-6):341-6. doi: 10.1159/000108575. Epub 2007 Sep 14. Oncology. 2006. PMID: 17855795 Clinical Trial.
TP53 mutations in advanced colorectal cancer: the dark side of the moon.
Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F, Maggi C, Montemurro G, Bossi I, Mariani L, de Braud F. Pietrantonio F, et al. Among authors: di bartolomeo m. Oncology. 2014;86(5-6):289-94. doi: 10.1159/000360088. Epub 2014 Jun 7. Oncology. 2014. PMID: 24924261
FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Pietrantonio F, Iacovelli R, Di Bartolomeo M, de Braud F. Pietrantonio F, et al. Among authors: di bartolomeo m. Lancet Oncol. 2014 Dec;15(13):e581. doi: 10.1016/S1470-2045(14)70397-3. Epub 2014 Nov 24. Lancet Oncol. 2014. PMID: 25456372 No abstract available.
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Pietrantonio F, et al. Among authors: di bartolomeo m. Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7. Oncologist. 2015. PMID: 26446234 Free PMC article.
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, Morano F, Picciani B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F. Pietrantonio F, et al. Among authors: di bartolomeo m. Clin Cancer Res. 2017 May 15;23(10):2414-2422. doi: 10.1158/1078-0432.CCR-16-1863. Epub 2016 Oct 25. Clin Cancer Res. 2017. PMID: 27780856 Free article.
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Berenato R, Morano F, Pietrantonio F, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, Battiston C, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, de Braud F, Mazzaferro V, Di Bartolomeo M. Berenato R, et al. Among authors: di bartolomeo m. Oncology. 2017;93(5):279-286. doi: 10.1159/000479154. Epub 2017 Sep 8. Oncology. 2017. PMID: 28881354 Clinical Trial.
254 results